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Genome-wide association studies (GWASs) have revealed increased breast cancer risk associated with multiple genetic variants at 5p12.
Here, we report the fine mapping of this locus using data from 104,660 subjects from 50 case-control studies in the Breast Cancer
Association Consortium (BCAC). With data for 3,365 genotyped and imputed SNPs across a 1 Mb region (positions 44,394,495–
45,364,167; NCBI build 37), we found evidence for at least three independent signals: the strongest signal, consisting of a single SNP
rs10941679, was associated with risk of estrogen receptor-positive (ERþ) breast cancer (per-g allele OR ERþ ¼ 1.15; 95% CI 1.13–1.18;
p ¼ 8.353 1030). After adjustment for rs10941679, we detected signal 2, consisting of 38 SNPs more strongly associated with ER-nega-
tive (ER) breast cancer (lead SNP rs6864776: per-a allele OR ER ¼ 1.10; 95% CI 1.05–1.14; p conditional ¼ 1.44 3 1012), and a single
signal 3 SNP (rs200229088: per-t allele OR ERþ ¼ 1.12; 95% CI 1.09–1.15; p conditional ¼ 1.12 3 1005). Expression quantitative trait
locus analysis in normal breast tissues and breast tumors showed that the g (risk) allele of rs10941679 was associated with increased
expression of FGF10 and MRPS30. Functional assays demonstrated that SNP rs10941679 maps to an enhancer element that physically
interacts with the FGF10 and MRPS30 promoter regions in breast cancer cell lines. FGF10 is an oncogene that binds to FGFR2 and is
overexpressed in ~10% of human breast cancers, whereas MRPS30 plays a key role in apoptosis. These data suggest that the strongest
signal of association at 5p12 is mediated through coordinated activation of FGF10 and MRPS30, two candidate genes for breast cancer
pathogenesis.
Strong evidence for the existence of a breast cancer (MIM:
114480) susceptibility locus at 5p12 has been observed
through a GWAS in Iceland (SNP rs7703618),1 in the Breast
Cancer Association Consortium (BCAC; SNP rs981782,
371 Kb centromeric),2 and in the Cancer GEnetic Markers
of Susceptibility study (CGEMS; SNP rs4866929; 352 Kb
1Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK; 2Cancer Division, QIMR Berghofer
Medical Research Institute, Brisbane, QLD 4006, Australia; 3Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care,
University of Cambridge, Cambridge CB1 8RN, UK; 4Department of Electron Microscopy/Molecular Pathology, The Cyprus Institute of Neurology and
Genetics, Nicosia 1683, Cyprus; 5Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0310 Oslo,
Norway; 6Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; 7Cancer Epidemiology Centre, Cancer
Council Victoria, Melbourne, VIC 3004, Australia; 8Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global health, The
University of Melbourne, Melbourne, VIC 3010, Australia; 9Department of Pathology, The University of Melbourne, Melbourne, VIC 3010, Australia;
10Institute of Population Health, University of Manchester, Manchester M13 9PL, UK; 11Division of Health Sciences, Warwick Medical School, Warwick
University, Coventry CV4 7AL, UK; 12Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlan-
gen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany; 13David Geffen School of Medicine, Department of Medicine
Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA 90095, USA; 14Toby Robins Breast Cancer Now Research
Centre, The Institute of Cancer Research, London SW3 6JB, UK; 15Division of Breast Cancer Research, The Institute of Cancer Research, London SW7 3RP,
UK; 16Research Oncology, Guy’s Hospital, King’s College London, London SE1 9RT, UK; 17Wellcome Trust Centre for Human Genetics and Oxford NIHR
Biomedical Research Centre, University of Oxford, Oxford OX3 7BN, UK; 18Department of Obstetrics and Gynecology, University of Heidelberg, 69120
Heidelberg, Germany; 19Molecular Epidemiology Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; 20National Center for Tu-
mor Diseases, University of Heidelberg, 69120 Heidelberg, Germany; 21Cancer & Environment Group, Center for Research in Epidemiology and Population
Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, 94807 Villejuif, France; 22Copenhagen General Population Study, Herlev and Gen-
tofte Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark; 23Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenha-
gen University Hospital, 2730 Herlev, Denmark; 24Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark;
(Affiliations continued on next page)
The American Journal of Human Genetics 99, 1–9, October 6, 2016 1
 2016 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Please cite this article in press as: Ghoussaini et al., Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen Receptor-
Positive Breast Cancer through FGF10 a..., The American Journal of Human Genetics (2016), http://dx.doi.org/10.1016/j.ajhg.2016.07.017
centromeric; r2 ¼ 0.18).3 A subsequent study, using 22
SNPs in ~5,000 case subjects and ~33,000 control subjects
of European ancestry, reported that risk at this locus could
be explained by two SNPs: rs4415084 and rs10941679.4
More recently, a BCAC study confirmed that rs10941679
was associated with risk of lower-grade, progesterone
receptor (PGR [MIM: 607311])-positive breast cancer
tumors.5
Here, we report the comprehensive fine-scale mapping
of this locus in 104,660 subjects from 50 case-control
studies participating in BCAC, including 41 studies from
populations of European ancestry and nine of East Asian
ancestry, and we explore the functional mechanisms
underlying the associations in this region. Genotyping
was conducted with the COGS array, a custom array
comprising approximately 200,000 SNPs.6 After quality-
control exclusions, we analyzed data from 48,155 case sub-
jects and 43,612 control subjects of European ancestry and
6,269 case subjects and 6,624 control subjects of Asian
ancestry. Estrogen receptor (ESR1 [MIM: 133430]) status
of the primary tumor was available for 27,748 European
and 4,997 Asian case subjects; of these, 7,646 (22%) Euro-
pean and 1,623 (32%) Asian case subjects were ER.
We examined a 1 Mb region (positions 44,394,495–
45,364,167; NCBI build 37 assembly) in which the 1000
Genomes Project cataloged 1,811 variants (March 2010
Pilot version 60 CEU project data). We aimed to genotype
all 628 SNPs with minor allele frequency (MAF) > 2% and
correlated with rs981782 and rs10941679 at r2 > 0.1 (n ¼
424), plus a set of SNPs designed to tag all remaining
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SNPs with r2 > 0.9 (n ¼ 184), but we managed to include
563 SNPs with a designability score (DS) > 0.9 and which
passed QC.6 IMPUTE v.2.0 was used to impute genotypes
of all known SNPs in the region using the 1000 Genome
Project data (March 2012 version) as a reference panel.
Case-control analyses were conducted on 3,365 SNPs
(563 genotyped and 2,776 imputed at r2 > 0.3). In Euro-
pean-ancestry women, 461 of these SNPs were associated
with overall breast cancer risk, 489 with ERþ and 38
with ER breast cancer risk (p < 104; Table S1). SNP
rs10941679 showed the strongest overall association
(MAF ¼ 0.27, per-minor (g) allele: OR ¼ 1.12; 95% CI
1.10–1.14; p ¼ 2.55 3 1026; Figure 1, Tables 1 and S1).
To identify additional association signals at this region,
we conducted a forward stepwise logistic regression exam-
ining SNPs with univariate p < 0.1 (n ¼ 1,040).6 The most
parsimonious model included three variants: SNP1
rs10941679 (signal 1), SNP2 rs6864776 (signal 2; condi-
tional p ¼ 6.22 3 1011), and SNP3 rs200229088 (signal
3; conditional p¼ 1.123 105, borderline significance; Ta-
ble S2). SNP1 and SNP3 are weakly correlated (r2 ¼ 0.15)
but SNP2 was uncorrelated with the other two (r2 ¼ 0.07
and 0.05).
The top signal, SNP1 rs10941679, is markedly more sig-
nificant than any other SNP in the locus (likelihood ratio>
10,000:1). Hence, the most parsimonious explanation is
that this SNP is causally related to risk. The next most
strongly associated SNP, after adjustment for signal 1 SNP
rs10941679, was rs6864776, representing signal 2 (OR
per minor allele ¼ 1.04; 95% CI 1.02–1.06; p ¼ 7.84 3
104; conditional p ¼ 1.44 3 1012). Within signal 2, a
further 37 SNPs correlated with rs6864776 at r2 > 0.6,
had likelihood ratios of <100:1 relative to rs6864776,
and hence could not be excluded from being causative
statistically (Table S2). After adjustment for both signal 1
SNP rs10941679 and signal 2 top SNP rs6864776, a single
SNP remained: rs200229088 (OR overall ¼ 1.09, 95%;
CI 1.07–1.12; p ¼ 2.28 3 1012; conditional p ¼ 1.12 3
105). There are no other SNPs correlated with
rs200229088 that could explain this association. All other
SNPs were excluded from causality (likelihood ratio >
10,000:1; Table S2). Two of the excluded variants had
been previously postulated as likely causative variants4,7
and so we investigated these in more depth. We found
both SNPs to be partially correlated with all three signals
and consequently display initially inflated effects, which
are adjusted by the conditional analyses. Thus, SNP
rs44150844 (r2 with signal 1 SNP rs10941679 ¼ 0.51,
with signal 2 SNP rs6864776 ¼ 0.11, and with signal 3
SNP rs200229088 ¼ 0.37) has odds against causality >
10 million:1 versus signal 1 candidate rs10941679. Simi-
larly, SNP rs7716600, which is an eQTL for MRPS30
expression7 (r2 with SNP rs10941679 ¼ 0.77, with SNP
rs6864776 ¼ 0.05, and with SNP rs200229088 ¼ 0.12)
has odds against causality >160,000:1 versus signal 1
candidate rs10941679. These exclusions of former causal
candidates highlight the need for fine-mapping studies
before conducting functional analyses.
Haplotype analyses were conducted using the above
three signal-representative variants, which generated eight
haplotypes (Table 2). Haplotypes carrying the rare allele of
signal 3 SNP rs200229088 conferred higher risks than
corresponding haplotypes carrying the common allele,
consistent with this allele having an independent effect.
Haplotype G, carrying the minor alleles of both the signal
1 and 2 representative SNPs, is very rare and reveals
that their risk alleles are negatively correlated, which is
also consistent with our finding that signal 2 top SNP
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rs6864776 increases in significance after conditioning on
signal 1 SNP rs10941679 (Table 1).
We examined the associations of these three SNPs in the
Asian case-control studies within BCAC. SNP1 and SNP3
both replicated in the Asian studies and the relative risk
estimates with overall breast cancer were consistent with
those seen in the European population: per g-allele OR
(rs10941679)¼ 1.09; 95%CI 1.04–1.15; p¼ 0.0009, condi-
tional p¼ 0.0859 and per t-allele OR (rs200229088)¼ 1.09;
95% CI 1.02–1.15; p ¼ 0.0065, conditional p ¼ 0.9149 (Ta-
ble 1). SNP2 was not replicated in Asians (per a-allele OR ¼
0.94; 95%CI 0.89–1.00; p¼ 0.034, conditional p¼ 0.8901)
(Table 1).
We investigated the associations of these three sig-
nals with tumor subtypes based on ER status. SNP1
rs10941679 was largely associated with ERþ breast cancer
(OR ERþ ¼ 1.15; 95%CI 1.13–1.18; p¼ 8.353 1030 versus
OR ER disease ¼ 1.04; 95% CI 1.00–1.08; p ¼ 0.059;
Figure 1. Manhattan Plot of the 5p12 Breast Cancer Susceptibility Locus
SNPs are plotted according to their chromosomal position on the x axis and their overall p values (log10 values, likelihood ratio test)
from the European BCAC studies (48,155 case and 43,612 control subjects) on the y axis. The purple dotted line intersects the y axis
at p ¼ 108 and indicates genome-wide significance. Candidate SNPs in signal 1 (rs10941679), signal 2 (38 SNPs), and signal 3
(rs200229088) are shown as short vertical lines. The locations of annotated genes and putative lncRNA transcripts from GENCODE
and enhancers predicted in Corradin et al.13 and Hnisz et al.12 from breast cancer cell lines are shown in the bottom panels.
Table 1. Associations of the Top SNPs from Each Signal with Overall Breast Cancer Risk and Breast Cancer Stratified by ER Status
Sig SNP Com Min MAF*
OR Overall
95% CI p Overall
Conditional
p Value OR ER p ER OR ERþ p ERþ
Europeans
1 rs10941679 A G 0.27 1.12 (1.10–1.14) 2.55 3 1026 6.55 3 1024 1.04 (1–1.08) 0.059 1.15 (1.13–1.18) 8.35 3 1030
2 rs6864776 G A 0.23 1.04 (1.02–1.06) 7.84 3 104 1.44 3 1012 1.10 (1.05–1.14) 2.5 3
105
1.02 (0.99–1.05) 0.08
3 rs200229088 TTG T 0.31 1.09 (1.07–1.12) 2.28 3 1012 1.12 3 105 1.03 (0.99–1.09) 0.11 1.12 (1.09–1.15) 7.51 3 1014
Asians
1 rs10941679 A G 0.50 1.09 (1.04–1.15) 9.12 3 104 0.0859 1.03 (0.95–1.11) 0.53 1.11 (1.04–1.18) 1.32 3 103
2 rs6864776 G A 0.32 0.94 (0.89–1.00) 3.47 3 102 0.8901 0.95 (0.87–1.04) 0.28 0.94 (0.89–1.00) 6.24 3 102
3 rs200229088 TTG T 0.37 1.09 (1.02–1.15) 6.52 3 103 0.9149 1.04 (0.95–1.14) 0.43 1.08 (1.00–1.16) 3.65 3 102
Abbreviations are as follows: Com, common alleles; Min, minor alleles; MAF, minor allele frequency; OR, per-allele odds ratios (OR); 95% CI, 95% confidence
intervals and 1 degree of freedom; p, significance levels for overall breast cancer are indicated in European and Asian case-control studies, and separately for
ERþ and ER disease.
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p heterogeneity ¼ 1.5 3 105; Table 1) as was SNP3
rs200229088 (OR ERþ ¼ 1.12; 95% CI 1.09–1.15; p ¼
7.51 3 1014 versus OR ER ¼ 1.03; 95% CI 0.99–1.09;
p ¼ 0.11, p heterogeneity ¼ 0.02). By contrast, SNP2
rs6864776 was moderately associated with ER but not
ERþ tumors (OR ER ¼ 1.10; 95% CI 1.05–1.14; p ¼
2.55 3 105 versus OR ERþ ¼ 1.02; 95% CI 0.99–1.05;
p ¼ 0.08; p heterogeneity ¼ 0.01; Table 1).
Candidate SNPs 1–3 span a 1.7 Mb region on 5p12 that
includes three annotated genes—FGF10 (MIM: 602115),
MRPS30 (MIM: 611991), and HCN1 (MIM: 602780)—and
several putative long noncoding RNAs (lncRNAs; Figure 1).
To identify potential target gene(s), we examined the asso-
ciations of the three lead SNPs with expression levels of
genes located within 1 Mb in three different studies: (1)
116 normal breast samples and 241 breast tumors from
the Norwegian Breast Cancer Study (NBCS),8 (2) 93 normal
and 765 breast cancer tissues from the TCGA study (germ-
line genotype data from Affymetrix SNP 6 array were
obtained from TCGA dbGAP data portal9), and (3) 183
normal breast samples from the Genotype-Tissue Expres-
sion (GTEx) project.10 The SNP1 rs10941679 risk-associ-
ated g-allele was moderately associated with increased
FGF10 mRNA expression in NBCS normal breast (p ¼
0.013, p corrected ¼ 0.39) and breast tumors (p ¼ 0.005,
p corrected ¼ 0.38) as well as in GTEx normal breast (p cor-
rected ¼ 0.02; Figures 2A and S1A). The effect in TCGAwas
in the same direction, though not significant (normal
breast p ¼ 0.353, p corrected ¼ 0.95 and breast tumors
p ¼ 0.057, p corrected ¼ 0.41; Figure S1B). The g-allele
was also associated with increased expression of MRPS30
in the NBCS normal (p ¼ 0.002, p corrected ¼ 0.36)
and breast tumors (p ¼ 0.049, p corrected ¼ 0.43), in
GTEx normal breast (p corrected ¼ 0.002), and in TCGA
(normal breast p ¼ 6.86 3 105, p corrected ¼ 5.31 3
103 and breast tumors p ¼ 7.21 3 106, p corrected ¼
9.35 3 104; Figures 2B, S1A, and S1C). No asso-
ciations were observed with SNP2 rs6864776 or SNP3
variant rs200229088. We also measured endogenous levels
of FGF10, MRPS30, and nearby lncRNAs FGF10-AS1,
BRCAT54, RP11-503D12.1, and RP11-473L15.3 mRNA in
breast cell lines homozygous (A/A or G/G) or heterozygous
(A/G) for the common allele of SNP1 (Table S3, Figures 2C,
2D, S2, and S3). Total RNA from cell lines was extracted
using Trizol and complementary DNA synthesized using
random primers as per manufacturers’ instructions. Quan-
titative PCR (qPCR) were performed using TaqMan assays
for FGF10 and MRPS30 normalized against beta-glucuron-
idase (GUSB [MIM: 611499]) or with SYTO9 for lncRNAs
normalized against TATA box-binding protein (TBP
[MIM: 600075]; primers are listed in Table S4). Although
the number of ERþ breast cell lines carrying the risk
allele was limited, FGF10 and MRPS30 mRNA levels were
significantly higher in the BT474 heterozygous cell line
(Figures 2C and 2D). BRCAT54was detected in themajority
of cell lines but its expression appears to be genotype inde-
pendent (Figure S3A). FGF10-AS1, RP11-503D12.1, and
RP11-473L15.3 transcripts were either expressed at very
low levels or not detected in the cell lines analyzed (Figures
S3B–S3D). Therefore, although we cannot rule out the pos-
sibility that the risk SNPs may influence local lncRNA
expression, the low or absent transcript levels precluded
any further evaluation.
Candidate causal SNPs were then explored using
publicly available datasets from ENCODE,11 which in-
cludes information such as the location of promoter and
enhancer histone marks, open chromatin, bound pro-
teins, and altered motifs for the MCF7 breast cancer cell
line, and from Hnisz et al.12 and Corradin et al.13 to iden-
tify the location of likely enhancers and their gene targets
in a cell-specific context. Analysis of cis enhancer-gene
interactions via PreSTIGE13 showed evidence of putative
regulatory elements (PREs) surrounding the top risk-asso-
ciated SNPs in MCF7 breast cancer cells, but no histone-
marked elements harboring a risk SNP in this cell line or
in a range of cell lines and tissues analyzed in Roadmap
(Figures 1 and S4). However, it is possible that certain
epigenetic marks may be detected only in a specific cell
subtype such as breast stem cells or in response to an
external stimulus.
Table 2. Haplotype Analysis across the BCAC Studies
Haplotypes
rs10941679
Signal 1
rs6864776
Signal 2
rs200229088
Signal 3
Haplotype
Frequency OR p Value
A 1 1 1 0.395440 – –
B 1 1 2 0.120099 1.06 (1.02–1.10) 1.49 3 103
C 1 2 1 0.199599 1.10 (1.06–1.13) 7.76 3 1011
D 1 2 2 0.018665 1.15 (1.04–1.27) 5.03 3 103
E 2 1 1 0.098169 1.14 (1.09–1.19) 1.45 3 1011
F 2 1 2 0.154525 1.20 (1.16–1.24) 2.72 3 1030
G 2 2 1 0.004248 0.91 (0.72–1.15) 4.15 3 101
H 2 2 2 0.009253 1.28 (1.10–1.48) 1.14 3 103
Each haplotype was compared to the ancestral haplotype carrying the common alleles of signal 1 SNP rs10941679, signal 2 SNP rs6864776, and signal 3 SNP
rs200229088 (haplotype A).
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To identify target gene(s), we performed chromatin
conformation capture (3C) assays in ERþ MCF7, BT474,
and MDA-MB-361 and ER MDA-MB-231 breast cancer
cell lines and Bre80 normal breast cells (Table S5).8 3C li-
braries were created by cross-linking the chromatin from
cell lines; DNA was then digested with EcoRI, which flanks
12 contiguous fragments that cover the PRE, and the
FGF10, MRPS30, and HCN1 promoters (Table S6); DNA
was religated and decrosslinked; and qPCR with primers
for the bait (gene promoters) and interactors (12 PRE frag-
ments) was performed to detect the presence of ligation
products, representing gene loops. BAC clones covering
the regions of interest were used to normalize for PCR effi-
ciency. These assays showed that the PRE containing SNP1
frequently interacted with the FGF10 and MRPS30 pro-
moter regions in MCF7 and BT474 breast cancer cell
lines, but only with MRPS30 in the MDA-MB-361, MDA-
MB-231, and Bre80 cell lines. This latter result was ex-
pected because FGF10 is not expressed or expressed at
very low levels in these cell lines (Figures 2C, 3A, S5, and
S6). Notably, both genes share a bidirectional promoter
with the lncRNAs FGF10-AS1 and BRCAT54, raising the
possibility that these transcripts are also targets of the
PRE (Figure 3A). No additional interactions were detected
between the PRE and other annotated genes within 1 Mb
of the PRE, including HCN1 (Figure S5). To assess the po-
tential impact of SNP1 on the identified chromatin inter-
actions, allele-specific 3C was performed in heterozygous
BT474 cell lines.8 However, the sequence profiles revealed
that SNP1 had no significant effect on chromatin looping
(Figure S7).
The regulatory capability of the PRE, combined with the
effect of SNP1, was further examined in reporter assays.
Promoter-driven luciferase reporter constructs were gener-
ated by the insertion of PCR-amplified fragments contain-
ing FGF10, FGF10-AS1, MRPS30, or BRCAT54 promoters
into pGL3-Basic.14 A 1,736-bp PRE fragment (containing
either the common or minor allele of rs10941679) was
then generated by PCR and cloned downstream of the
modified pGL3-promoter constructs (Table S7). MCF7
and BT474 breast cancer cell lines plus Bre80 normal breast
cells were transfected with the reporter plasmids and
luciferase activity was measured 24 hr after transfection.
To correct for any differences in transfection efficiency or
Figure 2. Association of rs10941679 with FGF10 andMRPS30 Expression in Normal Breast Tissues, Breast Tumors, and Breast Cancer
Cell Lines
(A and B) FGF10 (A) orMRPS30 (B) expression in normal breast (n ¼ 116) or breast tumors from NBCS dataset (n ¼ 241). SNP genotypes
are shown on the x axis and log2-normalized gene expression values on the y axis. p values are presented before and after correction for
multiple testing using FDR as implemented in p.adjust function in R. Each box plot shows the median rank normalized gene expression
(horizontal line), the first through third quartiles (box), and 1.53 the interquartile range (whiskers).
(C and D) Endogenous FGF10 (Hs00610298_m1) (C) or MRPS30 (Hs00169612_m1) (D) expression measured by qPCR in untreated
breast cell lines and normalized to GUSB (4326320E). Error bars denote SEM (n ¼ 3). p values were determined with a two-tailed
t test. **p < 0.01, ***p < 0.001.
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cell lysate preparation, Firefly luciferase activity was
normalized to Renilla. Notably, the ‘‘Ref PRE’’ acted as a
transcriptional enhancer, leading to a 2- to 3-fold increase
in FGF10, MRPS30, and BRCAT54 promoter activity, but
had no effect on the FGF10-AS1 promoter in MCF7 and
BT474 cells (Figures 3B and S8). The enhancer activity
was also observed for theMRPS30 and BRCAT54 promoters
in Bre80 cells (Figure S8). In all cell lines, inclusion of the
SNP1 risk (g) allele had no significant effect on the PRE
enhancer activity. Although this appears to rule out an ef-
fect of this SNP on transactivation, it is possible that SNP1
affects the recruitment of key proteins required for the
epigenetic modification of the enhancer, which would
not be observed in a reporter assay. Another possibility is
that the SNP effect may be observed only under certain
biological conditions such as growth factor stimulation.
To seek further evidence that SNP1 lies within an
enhancer element, we performed electrophoretic mobility
shift assays (EMSAs) for both the protective (a) and risk (g)
alleles.15 Nuclear lysates were prepared from ERþ BT474,
MCF7, and MDA-MB-361 or ER MDA-MB-231 and
Hs578T cells using the NE-PER nuclear and cytoplasmic
extraction reagents. Biotinylated oligonucleotide duplexes
were prepared by combining sense and antisense oligonu-
cleotides, heat annealing, and slow cooling. Duplex-bound
complexes were transferred onto Zeta-Probe positively
charged nylon membranes by semi-dry transfer then
cross-linked onto the membranes. Membranes were pro-
cessed with the LightShift Chemiluminescent EMSA kit
as per the manufacturer’s instructions, and signals were
visualized with the C-DiGit blot scanner. For SNP1, we
observed allele-specific binding by nuclear proteins only
in the ERþ BT474, MCF7, and MDA-MB-361 extracts (Fig-
ures 3C and S9). The protein-DNA complexes were shown
to be specific, as demonstrated by increasing amounts of
cold self-competitor (Figures 3C and S9 and Table S8).
FGF10 bait
A
FGF10 FGF10-AS1 MRPS30 BRCAT54 
PRE 
317kb 103kb 
rs10941679 
A G 
S
el
f-A
_ C
on
tro
l 
S
el
f-G
 
_ C
on
tro
l 
C
B
Relative luciferase activity
pGL3-basic
Ref PRE
FGF10 prom
rs10941679
Ref PRE
FGF10-AS1 prom
rs10941679
Ref PRE
MRPS30 prom
rs10941679
Ref PRE
BRCAT54 prom
rs10941679
***
3C
 in
te
ra
ct
io
n 
fre
qu
en
cy
MRPS30 bait
Chr 5 (Mb)44.682 44.735
Figure 3. Distal Regulation of FGF10 and MRPS30 at the 5p12 Risk Region
(A) 3C interaction profiles between the FGF10/FGF10AS-1 or MRPS30/BRCAT54 bidirectional promoters and the putative regulatory
element (PRE; gray bar) containing SNP rs10941679. Anchor points are set at the promoters. Graphs represent one of three independent
experiments (see Figure S5B). Error bars denote SD.
(B) Luciferase reporter assays after transient transfection of ERþ BT474 breast cancer cell lines. The PRE containing the major SNP allele
was cloned downstream of target gene promoter-driven luciferase constructs (Ref PRE). The risk g-allele was engineered into the con-
structs and designated by the rs ID. Primers are listed in Table S7. Error bars denote 95% confidence intervals from three independent
experiments. p values were determined by 2-way ANOVA followed by Dunnett’s multiple comparisons test (***p < 0.001).
(C) EMSA for oligonucleotides containing SNP rs1094617 with the A¼ common allele andG¼minor allele as indicated below the panel,
assayed using BT474 nuclear extracts. Primers are listed in Table S8. Labels above each lane indicate inclusion of competitor oligonucle-
otides at 30- and 100-fold molar excess, respectively: (-) no competitor and control denotes a non-specific competitor. A red arrowhead
shows a band of different mobility detected between the common and minor alleles.
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Further EMSAs using competitor DNA or antibody
supershifts against predicted transcription factors (TFs)
suggested four proteins bound to the SNP site including
FOXA1, FOXA2, CEBPB, and OCT1 (Figure S10 and Table
S9). To confirm TF binding in vivo, we performed chro-
matin immunoprecipitation (ChIP) in heterozygous
BT474 cells as previously described (Table S10).15 When
compared to an IgG control antibody, we observed a mod-
erate enrichment in FOXA1 and OCT1 binding to DNA
overlapping SNP rs10941679, but no difference between
alleles in this cell line (Figure S11). In addition, western
blot analysis indicated that FOXA1 protein expression
was restricted to the ERþ breast cancer cell lines analyzed,
whereas OCT1 was more widely expressed (Figure S12).
FOXA1 is a pioneer factor and master regulator of ER ac-
tivity due to its ability to open local chromatin and recruit
ER to target gene promoters.16 Notably, breast cancer-asso-
ciated SNPs are enriched for FOXA1 binding17 and several
studies have linked cooperative binding of FOXA1, ER, and
OCT1 to increased gene transcription.18,19 Consistent with
our eQTL data, it is tempting to speculate that in specific
ERþ cell subtypes and/or conditions, rs10941679 alters
FOXA1 affinity and OCT1 recruitment leading to target
gene activation.
In conclusion, we have provided evidence for at least
three independent causal SNPs with effects on the risk of
breast cancer at this locus. The minor g-allele of signal 1
SNP rs10941679 conferred a 15% increased risk of ERþ
breast cancer and higher expression levels of the MRPS30
and FGF10 genes and was the most strongly associated
SNP with MRPS30 expression in this 1 Mb region.
MRPS30—also called PDCD9 (Programmed Cell Death
protein 9)—encodes a mitochondrial ribosomal protein
involved in apoptosis.20 Although the role of mitochon-
dria in apoptosis remains unclear, it is well established
that cytochrome c and other pro-apoptotic proteins
are released during cell death initiation.20 Clearly, further
investigation of the function of this protein is now
merited. By contrast, FGF10 is an extensively studied
gene with compelling data suggesting its involvement in
breast tumorigenesis. FGF10 is a member of the fibroblast
growth factor (FGF) family and encodes a glycoprotein
that specifically binds to FGFR2 (splice FGFR2IIIb) to con-
trol signaling pathways including cell differentiation,
proliferation, and apoptosis.21 Variants regulating FGFR2
(MIM: 176943) have the strongest association with ERþ
breast cancer susceptibility identified to date.22 FGF10 is
overexpressed in ~10% of human breast cancers23 and
increased levels of FGF10 are highly correlated with pro-
liferation rate of breast cancer cell lines and cancer cell
invasion.24,25 It signals through multiple downstream
pathways including MAPK and WNT and genes such as
FGFR2, CCND1 (MIM: 168461), and TGFB1 (MIM:
190180),21,24 all known to play key roles in breast cancer.
Therapeutic targeting of FGFs and their receptors (FGFRs)
is currently a major area of drug development research,
and the identification of a subgroup of individuals diag-
nosed with breast cancer with alterations in these path-
ways may open new avenues for personalized medicine
and pathway-targeted treatments.
Supplemental Data
Supplemental Data include Supplemental Acknowledgments,
12 figures, 10 tables, and consortia information and can be found
with this article online at http://dx.doi.org/10.1016/j.ajhg.2016.
07.017.
Received: January 27, 2016
Accepted: July 16, 2016
Published: September 15, 2016
Web Resources
1000 Genomes, http://www.1000genomes.org
Cancer Cell Line Encyclopedia (CCLE), https://portals.
broadinstitute.org/ccle/home
ENCODE, https://www.encodeproject.org/
GEO, http://www.ncbi.nlm.nih.gov/geo/
GTEx Portal, http://www.gtexportal.org/home/
OMIM, http://www.omim.org/
PreSTIGE, http://genetics.case.edu/prestige/
The Cancer Genome Atlas, http://cancergenome.nih.gov/
References
1. Stacey, S.N., Manolescu, A., Sulem, P., Rafnar, T., Gudmunds-
son, J., Gudjonsson, S.A., Masson, G., Jakobsdottir, M., Thorla-
cius, S., Helgason, A., et al. (2007). Common variants on
chromosomes 2q35 and 16q12 confer susceptibility to estro-
gen receptor-positive breast cancer. Nat. Genet. 39, 865–869.
2. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D.,
Thompson, D., Ballinger, D.G., Struewing, J.P., Morrison, J.,
Field, H., Luben, R., et al.; SEARCH collaborators; kConFab;
AOCS Management Group (2007). Genome-wide association
study identifies novel breast cancer susceptibility loci. Nature
447, 1087–1093.
3. Hunter, D.J., Kraft, P., Jacobs, K.B., Cox, D.G., Yeager, M., Han-
kinson, S.E., Wacholder, S., Wang, Z., Welch, R., Hutchinson,
A., et al. (2007). A genome-wide association study identifies
alleles in FGFR2 associated with risk of sporadic postmeno-
pausal breast cancer. Nat. Genet. 39, 870–874.
4. Stacey, S.N., Manolescu, A., Sulem, P., Thorlacius, S., Gudjons-
son, S.A., Jonsson, G.F., Jakobsdottir, M., Bergthorsson, J.T.,
Gudmundsson, J., Aben, K.K., et al. (2008). Common variants
on chromosome 5p12 confer susceptibility to estrogen recep-
tor-positive breast cancer. Nat. Genet. 40, 703–706.
5. Milne, R.L., Goode, E.L., Garcı´a-Closas, M., Couch, F.J., Severi,
G., Hein, R., Fredericksen, Z., Malats, N., Zamora, M.P., Arias
Pe´rez, J.I., et al.; GENICA Network; kConFab Investigators;
AOCS Group (2011). Confirmation of 5p12 as a susceptibility
locus for progesterone-receptor-positive, lower grade breast
cancer. Cancer Epidemiol. Biomarkers Prev. 20, 2222–2231.
6. Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M.,
Dennis, J., Milne, R.L., Schmidt, M.K., Chang-Claude, J.,
Bojesen, S.E., Bolla, M.K., et al.; Breast and Ovarian Cancer
Susceptibility Collaboration; Hereditary Breast and Ovarian
Cancer Research Group Netherlands (HEBON); kConFab
8 The American Journal of Human Genetics 99, 1–9, October 6, 2016
Please cite this article in press as: Ghoussaini et al., Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen Receptor-
Positive Breast Cancer through FGF10 a..., The American Journal of Human Genetics (2016), http://dx.doi.org/10.1016/j.ajhg.2016.07.017
Investigators; Australian Ovarian Cancer Study Group;
GENICA (Gene Environment Interaction and Breast Cancer
in Germany) Network (2013). Large-scale genotyping iden-
tifies 41 new loci associated with breast cancer risk. Nat.
Genet. 45, 353–361, e1–e2.
7. Quigley, D.A., Fiorito, E., Nord, S., Van Loo, P., Alnæs, G.G.,
Fleischer, T., Tost, J., MoenVollan, H.K., Tramm, T., Overgaard,
J., et al. (2014). The 5p12 breast cancer susceptibility locus af-
fects MRPS30 expression in estrogen-receptor positive tumors.
Mol. Oncol. 8, 273–284.
8. Ghoussaini, M., Edwards, S.L., Michailidou, K., Nord, S., Cow-
per-Sal Lari, R., Desai, K., Kar, S., Hillman, K.M., Kaufmann, S.,
Glubb, D.M., et al.; Australian Ovarian Cancer Management
Group; Australian Ovarian Cancer Management Group
(2014). Evidence that breast cancer risk at the 2q35 locus is
mediated through IGFBP5 regulation. Nat. Commun. 4, 4999.
9. Li, Q., Seo, J.H., Stranger, B., McKenna, A., Pe’er, I., La-
framboise, T., Brown, M., Tyekucheva, S., and Freedman,
M.L. (2013). Integrative eQTL-based analyses reveal the
biology of breast cancer risk loci. Cell 152, 633–641.
10. Consortium, G.T.; GTEx Consortium (2013). The Genotype-
Tissue Expression (GTEx) project. Nat. Genet. 45, 580–585.
11. Birney, E., Stamatoyannopoulos, J.A., Dutta, A., Guigo´, R.,
Gingeras, T.R., Margulies, E.H., Weng, Z., Snyder, M., Dermit-
zakis, E.T., Thurman, R.E., et al.; ENCODE Project Con-
sortium; NISC Comparative Sequencing Program; Baylor
College of Medicine Human Genome Sequencing Center;
Washington University Genome Sequencing Center; Broad
Institute; Children’s Hospital Oakland Research Institute
(2007). Identification and analysis of functional elements in
1% of the human genome by the ENCODE pilot project. Na-
ture 447, 799–816.
12. Hnisz, D., Abraham, B.J., Lee, T.I., Lau, A., Saint-Andre´, V.,
Sigova, A.A., Hoke, H.A., and Young, R.A. (2013). Super-en-
hancers in the control of cell identity and disease. Cell 155,
934–947.
13. Corradin, O., Saiakhova, A., Akhtar-Zaidi, B., Myeroff, L., Wil-
lis, J., Cowper-Sal lari, R., Lupien, M., Markowitz, S., and Sca-
cheri, P.C. (2014). Combinatorial effects of multiple enhancer
variants in linkage disequilibrium dictate levels of gene
expression to confer susceptibility to common traits. Genome
Res. 24, 1–13.
14. Glubb, D.M., Maranian, M.J., Michailidou, K., Pooley, K.A.,
Meyer, K.B., Kar, S., Carlebur, S., O’Reilly, M., Betts, J.A., Hill-
man, K.M., et al.; GENICA Network; kConFab Investigators;
Norwegian Breast Cancer Study (2015). Fine-scale mapping
of the 5q11.2 breast cancer locus reveals at least three inde-
pendent risk variants regulating MAP3K1. Am. J. Hum. Genet.
96, 5–20.
15. Dunning, A.M., Michailidou, K., Kuchenbaecker, K.B.,
Thompson, D., French, J.D., Beesley, J., Healey, C.S., Kar, S.,
Pooley, K.A., Lopez-Knowles, E., et al.; EMBRACE; GEMO
Study Collaborators; HEBON; kConFab Investigators (2016).
Breast cancer risk variants at 6q25 display different phenotype
associations and regulate ESR1, RMND1 and CCDC170. Nat.
Genet. 48, 374–386.
16. Hurtado, A., Holmes, K.A., Ross-Innes, C.S., Schmidt, D., and
Carroll, J.S. (2011). FOXA1 is a key determinant of estrogen re-
ceptor function and endocrine response. Nat. Genet. 43, 27–33.
17. Cowper-Sal lari, R., Zhang, X., Wright, J.B., Bailey, S.D., Cole,
M.D., Eeckhoute, J., Moore, J.H., and Lupien,M. (2012). Breast
cancer risk-associated SNPs modulate the affinity of chro-
matin for FOXA1 and alter gene expression. Nat. Genet. 44,
1191–1198.
18. Meyer, K.B., Maia, A.T., O’Reilly, M., Teschendorff, A.E., Chin,
S.F., Caldas, C., and Ponder, B.A. (2008). Allele-specific up-
regulation of FGFR2 increases susceptibility to breast cancer.
PLoS Biol. 6, e108.
19. Belikov, S., Astrand, C., andWrange, O. (2009). FoxA1 binding
directs chromatin structure and the functional response of a
glucocorticoid receptor-regulated promoter. Mol. Cell. Biol.
29, 5413–5425.
20. Cavdar Koc, E., Ranasinghe, A., Burkhart, W., Blackburn, K.,
Koc, H., Moseley, A., and Spremulli, L.L. (2001). A new face
on apoptosis: death-associated protein 3 and PDCD9 aremito-
chondrial ribosomal proteins. FEBS Lett. 492, 166–170.
21. Turner, N., and Grose, R. (2010). Fibroblast growth factor
signalling: from development to cancer. Nat. Rev. Cancer 10,
116–129.
22. Meyer, K.B., O’Reilly, M., Michailidou, K., Carlebur, S., Ed-
wards, S.L., French, J.D., Prathalingham, R., Dennis, J., Bolla,
M.K., Wang, Q., et al.; GENICA Network; kConFab Investiga-
tors; Australian Ovarian Cancer Study Group (2013). Fine-
scale mapping of the FGFR2 breast cancer risk locus: putative
functional variants differentially bind FOXA1 and E2F1. Am.
J. Hum. Genet. 93, 1046–1060.
23. Theodorou, V., Boer, M., Weigelt, B., Jonkers, J., van der Valk,
M., and Hilkens, J. (2004). Fgf10 is an oncogene activated by
MMTV insertional mutagenesis in mouse mammary tumors
and overexpressed in a subset of human breast carcinomas.
Oncogene 23, 6047–6055.
24. Abolhassani, A., Riazi, G.H., Azizi, E., Amanpour, S., Muham-
madnejad, S., Haddadi, M., Zekri, A., and Shirkoohi, R. (2014).
FGF10: type III epithelial mesenchymal transition and inva-
sion in breast cancer cell lines. J. Cancer 5, 537–547.
25. Chioni, A.M., and Grose, R. (2009). Negative regulation of
fibroblast growth factor 10 (FGF-10) by polyoma enhancer
activator 3 (PEA3). Eur. J. Cell Biol. 88, 371–384.
The American Journal of Human Genetics 99, 1–9, October 6, 2016 9
Please cite this article in press as: Ghoussaini et al., Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen Receptor-
Positive Breast Cancer through FGF10 a..., The American Journal of Human Genetics (2016), http://dx.doi.org/10.1016/j.ajhg.2016.07.017
